The Molecular Genetics Program conducts fundamental research on the etiology, progression, prevention, detection, and treatment of cancer with the goal of using the Cancer Center to translate these fundamental discoveries to our patients and population resources. The scientific focus of this group of 24 faculty members is on DMA damage, chromosomal translocation sites, chromosomal fragile sites, DMA repair mechanisms and proteins, DNA replication mechanisms and proteins, familial cancer gene identification, and mammalian cancer models. The 24 member group from 10 academic departments in three schools has Minisymposia, Cancer Center Strategy Sessions, weekly data presentation meetings, and annual poster sessions in addition to the weekly Cancer Center Grand Rounds, as forums for interaction. For purposes of developing program projects and other grants, the Molecular Genetics Program is subdivided into three focus groups: DNA Repair, DNA Replication, and Cancer Genetic Models. Many major cancer research discoveries have been made in the previous funding interval. New DNA repair proteins have been identified, and these are being explored as possible chemotherapy drug targets. The basis for the most common chromosomal translocation in human cancer was defined as being due to a triplex DNA structure. An entire class of DNA polymerases was defined. Collaborations within the Program have shown that these polymerases participate in the major pathway of double-strand break repair. A program project on polymerase active sites was secured and will permit rationale design of polymerase inhibitors for cancer chemotherapy. Marked progress has also been made in understanding the persistence of hepatitis viruses, which are important in causing hepatocellular carcinoma. Other Program members are collaborating to study cancer genetic models of prostate and ovarian cancers and have developed a conditional knockout mouse, widely regarded as being the best currently available for prostate cancer. Genetic linkage analysis of prostate cancer families is underway, and is integrated into an international consortium. Hence, both scientific collaborations and cancer research discoveries are facilitated by the existence of the Molecular Genetics Program. Of the 212 publications over the last five years, 10.4% were intraprogrammatic collaborations and 10.4% were interprogrammatic collaborations. The Program is supported by $6.3 million in direct peer-reviewed support per year of which $2.1 million is from the NCI.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014089-33
Application #
7726549
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2007-12-01
Budget End
2008-11-30
Support Year
33
Fiscal Year
2008
Total Cost
$381,691
Indirect Cost
Name
University of Southern California
Department
Type
DUNS #
072933393
City
Los Angeles
State
CA
Country
United States
Zip Code
90089
Ricker, Charité N; Koff, Rachel B; Qu, Chenxu et al. (2018) Patient communication of cancer genetic test results in a diverse population. Transl Behav Med 8:85-94
Valentin-Torres, Alice; Savarin, Carine; Barnett, Joslyn et al. (2018) Blockade of sustained tumor necrosis factor in a transgenic model of progressive autoimmune encephalomyelitis limits oligodendrocyte apoptosis and promotes oligodendrocyte maturation. J Neuroinflammation 15:121
Tobin, Jessica; Miller, Kimberly A; Baezconde-Garbanati, Lourdes et al. (2018) Acculturation, Mental Health, and Quality of Life among Hispanic Childhood Cancer Survivors: A Latent Class Analysis. Ethn Dis 28:55-60
Jayne, Jordanna G; Bensman, Timothy J; Schaal, Justin B et al. (2018) Rhesus ?-Defensin-1 Attenuates Endotoxin-induced Acute Lung Injury by Inhibiting Proinflammatory Cytokines and Neutrophil Recruitment. Am J Respir Cell Mol Biol 58:310-319
Lee, Brian H; Stallcup, Michael R (2018) Different chromatin and DNA sequence characteristics define glucocorticoid receptor binding sites that are blocked or not blocked by coregulator Hic-5. PLoS One 13:e0196965
Harris, Holly R; Babic, Ana; Webb, Penelope M et al. (2018) Polycystic Ovary Syndrome, Oligomenorrhea, and Risk of Ovarian Cancer Histotypes: Evidence from the Ovarian Cancer Association Consortium. Cancer Epidemiol Biomarkers Prev 27:174-182
Woodham, Andrew W; Cheloha, Ross W; Ling, Jingjing et al. (2018) Nanobody-Antigen Conjugates Elicit HPV-Specific Antitumor Immune Responses. Cancer Immunol Res 6:870-880
Matsusaka, S; Wu, A H; Cao, S et al. (2018) Prognostic impact of FOXF1 polymorphisms in gastric cancer patients. Pharmacogenomics J 18:262-269
Vannini, Ivan; Fanini, Francesca; Fabbri, Muller (2018) Emerging roles of microRNAs in cancer. Curr Opin Genet Dev 48:128-133
Veyseh, Maedah; Ricker, Charite; Espenschied, Carin et al. (2018) Secondary Germline Finding in Liquid Biopsy of a Deceased Patient; Case Report and Review of the Literature. Front Oncol 8:259

Showing the most recent 10 out of 842 publications